Dose Escalation Using CHARTWEL in Non-Small-Cell Lung Cancer
Author Information
Author(s): MI Saunders, A Rojas, BE Lyn, K Pigott, M Powell, K Goodchild, PJ Hoskin, H Phillips, N Verma
Primary Institution: Marie Curie Research Wing, Mount Vernon Hospital
Hypothesis
Can a modified CHART schedule improve survival and reduce morbidity in non-small-cell lung cancer?
Conclusion
Increasing the radiation dose in the CHARTWEL schedule led to higher acute oesophageal morbidity and mild late lung dysfunction, but did not require more intensive medical management.
Supporting Evidence
- Patients treated with CHARTWEL 60 Gy experienced more severe dysphagia than those treated with 54 Gy.
- 60% of patients died due to failure to control locoregional disease.
- Acute dysphagia and analgesia were more severe and lasted longer in patients treated with CHARTWEL 60 Gy.
- At 12 weeks, oesophagitis was similar between both treatment groups.
- Over 80% of patients treated with CHARTWEL 60 Gy showed some degree of lung impairment after two years.
Takeaway
Doctors tested a new way to give radiation to lung cancer patients and found that while it caused more side effects, it didn't make patients worse off overall.
Methodology
Patients were treated with either 54 Gy in 16 days or 60 Gy in 18 days, and their symptoms were monitored for acute and late morbidity.
Potential Biases
Potential selection bias in patient eligibility for the study.
Limitations
The study had a small sample size and was limited to specific patient demographics.
Participant Demographics
64 patients, 49 men and 15 women, aged 45-80 years (median 66 years).
Statistical Information
P-Value
0.004
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website